Rene Wipperich – CEO, Galderma Korea
Rene Wipperich took the helm of Galderma’s Korean affiliate in August 2018. He breaks down the performance of the affiliate across its four business segments and the main competitive advantages…
Address: Seoul Namdaemunno 5 84-11 bungee Yonsei Foundation Severance Building, 18th floor (Right) 100-753 ,Republic of Korea
Tel: 02) 768-9000/9114
Novartis Republic of Korea is a 500-employee strong organization that registered a turnover of US$294 million in 2007 (272 billion won) and is dedicated to marketing, sales — and research. Headquartered in Basel, Switzerland, the company was created in 1996 through the merger of two former Swiss giants in the pharmaceutical field, Ciba-Geigy and Sandoz. The history of Novartis in Republic of Korea began in 1984 with the arrival of this latter entity. Today, the company maintains a presence through four divisions: Pharmaceuticals; Vaccines & Diagnostics; Sandoz Republic of Korea (a separate legal entity), the only multinational generic drug company in Republic of Korea and the result of rebranding effort to give the Sandoz name a new identity as a generics portfolio; and Consumer Health, which deals with over-the-counter healthcare and lifestyle products such as CIBA Vision (also a separate legal entity) contact lenses.Major products of Novartis Republic of Korea include hypertension treatments Diovan, Co-Diovan, and Exforge, this latter in copromotion with Pfizer; Glivec, a drug to combat chronic myeloid leukemia (CML); Neoral, an immune system suppressant for use with transplant patients; Lescol, a preparation to treat hyperlipidemia; Femara, to prevent the reoccurrence of breast cancer following surgery; and new products Lucentis used to treat wet age-related macular degeneration (AMD), a sight-degeneration condition, Exelon Patch (Alzheimer’s dementia) and Aclasta (osteoporosis).
Rene Wipperich took the helm of Galderma’s Korean affiliate in August 2018. He breaks down the performance of the affiliate across its four business segments and the main competitive advantages…
YD Global Life Science is a Korean biopharmaceutical company with ambitions to become a global leader in new drug development with USD 1 billion in revenues. Its founder & CEO,…
Bernhard Brender, general manager of Grand Hilton Seoul, discusses the role of his conference centre and the meetings, incentives, conferences and exhibitions (MICE) industry in general in the economic development…
Thibault Janssens, managing director of Bolloré Logistics Korea, shares his expert opinion on the Asian logistics market, and explains how a constant customer-centric focus catering to the specific needs of…
Kukjeon, originally a leading Korean pharmaceutical wholesaler, has in recent years expanded into API manufacturing. Its president, Jay Hong, explains his high-risk strategy to pursue new API business opportunities, and…
YH Shin, CEO of Dr.G, one of Korea’s most successful dermo-cosmetic brands, shares the reasons why he decided to become a dermatologist and later start his own cosmetic company. He…
Historically, Handok has been the entry point of multinational companies to Korea. Now Handok is reinventing itself as a total healthcare company with global ambitions. Its chairman and CEO, Young-jin…
Nic Horridge was recently appointed president of Roche Korea, having spent an extended period in emerging Asian markets. He shares his vision for the Korean affiliate, focused on bringing Roche’s…
iCure is a Korean company applying its advanced transdermal delivery technology to pharmaceuticals and dermo-cosmetics. The company has developed the first-ever transdermal patch for donepezil to reach Phase III clinical…
Myung-Kyu Lee, vice president of the Korea Cosmetic Association, explains how the association helps its member companies both at home and abroad, breaks down the implications of new local and…
Shin Poong is one of the oldest pharmaceutical companies in Korea. Established after the Korean War, the company’s original mission was to provide high-quality and affordable generic medicines to the…
Cure Therapeutics is a startup developing gene and cell therapies in Korea. Its founder David Kim explains where his passion for regenerative therapies stems from, breaks down the main hurdles…
See our Cookie Privacy Policy Here
